WE CLAIM:

1. An indole compound represented by the formula (I), or a pharmaceutically acceptable salt, solvate, or prodrug derivative thereof;



(I)

wherein ;

R_1 is selected from groups (a), (b), and (c) wherein;

(a) is C_7-C_{20} alkyl, C_7-C_{20} haloalkyl, C_7-C_{20} alkenyl, C_7-C_{20} alkynyl, carbocyclic radical, or heterocyclic radical, or

(b) is a member of (a) substituted with one or more independently selected non-interfering substituents; or

(c) is the group $-(L_1)-R_{11}$; where, $-(L_1)-$ is a divalent linking group of 1 to 8 atoms and where R_{11} is a group selected from (a) or (b);

R_2 is hydrogen, or a group containing 1 to 4 non-hydrogen atoms plus any required hydrogen atoms;

R_3 is $-(L_3)-$ Z, where $-(L_3)-$ is a divalent linker group selected from a bond or a divalent group selected from:



and Z is selected from a group represented by the formulae,





or



wherein, X is oxygen or sulfur; and R_a is selected from hydrogen, C_1-C_8 alkyl, aryl, C_1-C_8 alkaryl, C_1-C_8 alkoxy, aralkyl and -CN;

R_4 is the group, -(L_h)-(hydroxyfunctional amide); wherein -(L_h)-, is an hydroxyfunctional amide linker having an hydroxyfunctional amide linker length of 1 to 8;

R_5 is selected from hydrogen, a non-interfering substituent, or the group, -(L_a)-(acidic group); wherein -(L_a)-, is an acid linker having an acid linker length of 1 to 8;

R_6 and R_7 are selected from hydrogen, non-interfering substituent, carbocyclic radical, carbocyclic radical substituted with non-interfering substituent(s), heterocyclic radicals, and heterocyclic radical substituted with non-interfering substituent(s).

2. The compound of claim 1 wherein R_2 is hydrogen, C_1-C_4 alkyl, C_2-C_4 alkenyl, -O-(C_1-C_3 alkyl), -S-(C_1-C_3 alkyl), C_3-C_4 cycloalkyl, $-CF_3$, halo, $-NO_2$, -CN, or $-SO_3$.

3. The compound of Claim 1 wherein the hydroxyfunctional amide linker group, -(L_h)-, for R_4 is selected from a group represented by the formula;



where Q_2 is selected from the group -(CH_2)-, -O-, -NH-, -C(O)-, and -S-, and each R_{40} is independently selected

from hydrogen, C_1-C_8 alkyl, aryl, C_1-C_8 alkaryl, C_1-C_8 alkoxy, aralkyl, and halo.

4. The compound of Claim 1 wherein the hydroxyfunctional amide linker group, -(Lh)-, for R_4 is a divalent group selected from,



,



,



,



,

or



where R_{40}, R_{41}, R_{42}, and R_{43} are each independently selected from hydrogen, C_1-C_8 alkyl.

5. The compound of Claim 1 wherein the acid linker, -(L_a)-, for R_5 is selected from a group represented by the formulae consisting of;



,



,













and



;

wherein R_{54}, R_{55}, R_{56} and R_{57} are each independently hydrogen, C_1-C_8 alkyl, C_1-C_8 haloalkyl, aryl, C_1-C_8 alkoxy, or halo.

6. The compound of claim 1 wherein R_5 is the group, -(L_a)-(acidic group) and wherein the (acidic group) is selected from the group:

-5-tetrazolyl,

$-SO_3H$,



,


O
P
OH
OR80


O
O
P
OH
OR80


O
P
OH
OH


O
O
P
OH
OH





or



where R_{80} is a metal or C_1-C_8 alkyl and R_{81} is an organic substituent or $-CF_3$.

7. The compound of claim 1 wherein for R_3, Z is the group represented by the formula;



and the linking group $-(L_3)-$ is a bond; and R_a is hydrogen, methyl, ethyl, propyl, isopropyl, phenyl or benzyl.

8. The compound of claim 1 wherein for R_3, Z is the group represented by the formula;



and the linking group -(L_3)- is a bond; and R_a is hydrogen.

9. The compound of claim 1 wherein for R_3, Z is the group represented by the formula;



and the linking group -(L_3)- is a bond.

10. The compound of claim 1 wherein for R_3, Z is the group represented by the formula;



and the linking group -(L_3)- is a bond.

11. The compound of Claim 1 wherein, for R_6 the non-interfering substituent is hydrogen, C_1-C_8 alkyl, C_2-C_8 alkenyl, C_2-C_8 alkynyl, C_7-C_{12} aralkyl, C_7-C_{12} alkaryl, C_3-C_8 cycloalkyl, C_3-C_8 cycloalkenyl, phenyl, tolulyl, xylenyl, biphenyl, C_1-C_8 alkoxy, C_2-C_8 alkenyloxy, C_2-C_8 alkynyloxy, C_2-C_{12} alkoxyalkyl, C_2-C_{12} alkoxyalkyloxy, C_2-C_{12} alkylcarbonyl, C_2-C_{12} alkylcarbonylamino, C_2-C_{12} alkoxyamino, C_2-C_{12} alkoxyaminocarbonyl, C_1-C_{12}

alkylamino, C_1-C_6 alkylthio, C_2-C_{12} alkylthiocarbonyl, C_1-C_8 alkylsulfinyl, C_1-C_8 alkylsulfonyl, C_2-C_8 haloalkoxy, C_1-C_8 haloalkylsulfonyl, C_2-C_8 haloalkyl, C_1-C_8 hydroxyalkyl, -C(O)O(C_1-C_8 alkyl), -$(CH_2)_n$-O-(C_1-C_8 alkyl), benzyloxy, phenoxy, phenylthio, -($CONHSO_2R$), -CHO, amino, amidino, bromo, carbamyl, carboxyl, carbalkoxy, -$(CH_2)_n$-CO_2H, chloro, cyano, cyanoguanidinyl, fluoro, guanidino, hydrazide, hydrazino, hydrazido, hydroxy, hydroxyamino, iodo, nitro, phosphono, -SO_3H, thioacetal, thiocarbonyl, or carbonyl; where n is from 1 to 8.

12. The compound of Claim 1 wherein for R_1 the divalent linking group -(L_1)- is selected from a group represented by the formulae (Ia), (Ib), (Ic), (Id), (Ie), and (If):


(Ia)

(Ib)

(Ic)

or (Id)

(Ie)

or


(If)

where Q_1 is a bond or any of the divalent groups Ia, Ib, Ic, Id, and Ie and R_{10} is independently -H, C_{1-8} alkyl, C_{1-8} haloalkyl or C_{1-8} alkoxy.

13. The compound of claim 1 wherein the linking group $-(L_1)-$ of R_1 is $-(CH_2)-$ or $-(CH_2-CH_2)-$.

14. The compound of claim 1 wherein the linking group $-(L_{11})-$ of R_{11} is a bond and R_{11} is $-(CH_2)m-R^{12}$ wherein m is an integer from 1 to 6, and R^{12} is a group represented by the formula:



wherein a, c, e, n, q, and t are independently an integer from 0 to 2, R^{13} and R^{14} are independently selected from a halogen, C_1 to C_8 alkyl, C_1 to C_8 alkyloxy, C_1 to C_8 alkylthio, aryl, heteroaryl, and C_1 to C_8 haloalkyl, α is an oxygen atom or a sulfur atom, L^5 is a bond, $-(CH_2)v-$,

-C=C-, -CC-, -O-, or -S-, v is an integer from 0 to 2, β is $-CH_2-$ or $-(CH_2)_2-$, γ is an oxygen atom or a sulfur atom, b is an integer from 0 to 3, d is an integer from 0 to 4, f, p, and w are independently an integer from 0 to 5, r is an integer from 0 to 7, and u is an integer from 0 to 4, or is (e) a member of (d) substituted with at least one substituent selected from the group consisting of C_1 to C_6 alkyl, C_1 to C_8 alkyloxy, C_1 to C_8 haloalkyloxy, C_1 to C_8 haloalkyl, aryl, and a halogen..

15. The compound of claim 1 wherein for R_1 the group R_{11} is a substituted or unsubstituted carbocyclic radical selected from the group consisting of cycloalkyl, cycloalkenyl, phenyl, spiro[5.5]undecanyl, naphthyl, norbornanyl, bicycloheptadienyl, tolulyl, xylenyl, indenyl, stilbenyl, terphenylyl, diphenylethylenyl, phenyl-cyclohexenyl, acenaphthylenyl, and anthracenyl, biphenyl, bibenzylyl and related bibenzylyl homologues represented by the formula (a):



(a)

where n is a number from 1 to 8.

16. The compound of Claim 12 wherein for R_1 the combined group $-(L_1)-R_{11}$ is selected from the groups;



or



where R_{12} is a radical independently selected from halo, C_1-C_{10} alkyl, C_1-C_{10} alkoxy, -S-(C_1-C_{10} alkyl), and C_1-C_{10} haloalkyl, C_1-C_{10} hydroxyalkyl and t is a number from 0 to 5 and u is a number from 0 to 4.

17. The compound of claim 1 wherein for R_1 the radical R_{11} is a substituted or unsubstituted heterocyclic radical selected from pyrrolyl, pyrrolodinyl, piperidinyl, furanyl, thiophenyl, pyrazolyl, imidazolyl, phenylimidazolyl, triazolyl, isoxazolyl, oxazolyl, thiazolyl, thiadiazolyl, indolyl, carbazolyl, norharmanyl, azaindolyl, benzofuranyl, dibenzofuranyl, dibenzothiophenyl, indazolyl, imidazo(1.2-A)pyridinyl, benzotriazolyl, anthranilyl, 1,2-benzisoxazolyl, benzoxazolyl, benzothiazolyl, purinyl, pyridinyl, dipyridylyl. phenylpyridinyl, benzylpyridinyl, pyrimidinyl, phenylpyrimidinyl, pyrazinyl, 1,3,5-triazinyl, quinolinyl, phthalazinyl, quinazolinyl-morpholino, thiomorpholino, homopiperazinyl, tetrahydrofuranyl, tetrahydropyranyl, oxacanyl, 1,3-dioxolanyl, 1,3-dioxanyl, 1,4-dioxanyl, tetrahydrothiopheneyl, pentamethylenesulfadyl, 1,3-dithianyl, 1,4-dithianyl, 1,4-thioxanyl, azetidinyl,

hexamethyleneiminium, heptamethyleneiminium, piperazinyl or quinoxalinyl.

18. The compound of claim 1 wherein R_4 is the group, $-(L_C)-$(hydroxyfunctional amide group) and wherein the (hydroxyfunctional amide group) is:



and R^{4a} is independently selected from the group consisting of OH, (C_1-C_6)alkoxy, (C_7-C_{14})alkaryloxy, (C_2-C_8)alkenyloxy, (C_7-C_{14}) aralkyloxy, (C_7-C_{14})aralkenyloxy and aryloxy; and wherein R^{4b} is independently selected from the group consisting of H, (C_1-C_6)alkyl, arylalkyl, heteroaryl and aryl.

19. An indole compound represented by the formula (II), or a pharmaceutically acceptable salt, solvate, or prodrug derivative thereof;



(II)

wherein ;

R_{22} is selected from hydrogen, methyl, ethyl, propyl, isopropyl, cyclopropyl, -F, $-CF_3$, -Cl, -Br, or $-O-CH_3$;

R^{4a} is independently selected from the group consisting of OH, (C_1-C_6)alkoxy, (C_7-C_{14})alkaryloxy, (C_2-C_8)alkenyloxy, (C_7-C_{14}) aralkyloxy, (C_7-C_{14})aralkenyloxy and aryloxy; and R^{4b} is H, (C_1-C_6)alkyl, arylalkyl, heteroaryl or aryl ; and $-(L_h)-$ is a divalent group selected from;



,



,





or



where R_{40}, R_{41}, R_{42}, and R_{43} are each independently selected from hydrogen or C_1-C_8 alkyl.

R_{16} is selected from hydrogen, C_1-C_8 alkyl, C_1-C_8 alkoxy, C_1-C_8 alkylthio C_1-C_8 haloalkyl, C_1-C_8 hydroxyalkyl, and halo.

R_{13} is selected from hydrogen and C_1-C_8 alkyl, C_1-C_8 alkoxy, -S-(C_1-C_8 alkyl), C_1-C_8 haloalkyl, C_1-C_8 hydroxyalkyl, phenyl, halophenyl, and halo, and t is an integer from 0 to 5.

20. A compound of claim 1 selected from the group consisiting of:

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylm thyl)-1H-indol-4-yl]oxy]-*N*-(hydroxy)acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-(methyloxy)acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-(methyl)-*N*-(methyloxy)acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-(hydroxy)-*N*-(methyl)acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-(ethyloxy)acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-(2-propenyloxy)acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-(hydroxy)-*N*-(2-propyl)acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-(tert-butyloxy)acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-[2-(methyl)propyloxy]acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-(phenylmethyloxy)acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-(methyl)-*N*-(phenylmethyloxy)acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-(phenyloxy)acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-(methyl)-*N*-(phenyloxy)acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-(cyclohexyl)-*N*-(hydroxy)acetamide; and

2-[[3-(2-Amino-2-oxoethyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-(hydroxy)acetamide.

21. An indole compound represented by the formulae (C1), (C2), (C3), (C4), (C5), (C6), (C7), (C8), (C9), (C10), (C11), (C12), (C13), (C14) or (C15);



(C1),



(C2),



(C3),



(C4),



(C5),



(C6),



(C7),



(C8),



(C9),



(C10),



(C11),



(C12),



(C13),



(C14), and



(C15)

or pharmaceutically acceptable salts or prodrugs thereof.

22. A pharmaceutical formulation comprising a indole compound as claimed in claim 1 together with a pharmaceutically acceptable carrier or diluent therefor.

23. A method of inhibiting $sPLA_2$ mediated release of fatty acid comprising: contacting $sPLA_2$ with a therapeutically effective amount of indole compound as claimed in claim 1.

24. A method of treating a mammal, including a human, to alleviate the pathological effects of Inflammatory Diseases; wherein the method comprises administering to said mammal a thrapeutically effective amount of an indole compound as claimed in Claim 1.

25. A compound of claim 1 or a pharmaceutical formulation containing an effective amount of the compound of claim 1 useful for the treatment and/or amelioration of Inflammatory Diseases.

26. A compound of claim 1 or a pharmaceutical formulation containing an effective amount of the compound of claim 1 for useful for inhibiting $sPLA_2$ mediated release of fatty acid.

27. Use of a pharmaceutical composition comprising $sPLA_2$ inhibitor compounds according to Claim 1 and mixtures thereof for the manufacture of a medicament for the treatment of Inflammatory Diseases.